Skip to main content
Fig. 7 | The Journal of Headache and Pain

Fig. 7

From: Therapeutic novelties in migraine: new drugs, new hope?

Fig. 7

Overview of patients (%) achieving > 50% reduction in migraine days in phase III clinical trials with erenumab. A darker bar indicates a higher dose. *ARISE; 70 mg vs. placebo, p = 0.010. STRIVE; 70 mg vs. placebo, p < 0.001; 140 mg vs. placebo, p < 0.001

Back to article page